Consensus TERT Immunogenic Composition for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are often ineffective in preventing and treating cancer, leading to limited success in delaying disease progression and reducing mortality.
Innovation Solution
Development of an immunogenic composition comprising a nucleic acid molecule encoding a consensus TERT antigen, combined with immune checkpoint inhibitors and adjuvants like IL-12, IL-15, or RANTES, to stimulate an immune response against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments (chemotherapy, radiation therapy, surgical removal) are used, then treatment can be administered, but effectiveness in preventing and treating cancer is limited
Solution Approach 1:
The patent uses adjuvants as intermediary substances to enhance the immune system's natural ability to fight cancer. These adjuvants mediate between the antigen (cancer target) and the immune response, boosting effectiveness without requiring complex conventional treatment protocols. The adjuvant acts as a catalyst that amplifies the body's own defensive mechanisms.
Solution Approach 2:
The invention leverages the body's own immune system to fight cancer, rather than imposing external treatment forces. By stimulating the immune system with antigens and adjuvants, the body performs self-service in detecting and eliminating cancer cells, reducing reliance on complex external interventions like chemotherapy or radiation.
2Reliability
If immunogenic composition with multiple components (TERT antigen, adjuvants, checkpoint inhibitors) is used, then immune response is enhanced, but composition complexity increases
Solution Approach 1:
The patent combines multiple immunological components (TERT antigen, adjuvants, and immune checkpoint inhibitors) into a single integrated composition. This merging approach allows the components to work synergistically, where the adjuvant enhances antigen presentation while checkpoint inhibitors remove braking signals, creating a coordinated immune response that is greater than the sum of individual parts.
Solution Approach 2:
The immunogenic composition functions as a composite biological material, combining different types of molecules (proteins, nucleic acids, cytokines) with distinct functions. Each component contributes specific properties: the antigen provides target specificity, adjuvants provide immunostimulation, and checkpoint inhibitors provide immune activation, creating a multifunctional therapeutic agent.
Data Source
AI summary
Disclosed herein are compositions comprising optimized consensus TERT antigens and methods for treating cancer and in particular immunogenic compositions that treat and provide protection against tumor.